292,778 Shares in Taysha Gene Therapies, Inc. $TSHA Purchased by Kovitz Investment Group Partners LLC

Key Points

• Kovitz Investment Group Partners LLC has invested $407,000 in Taysha Gene Therapies, acquiring 292,778 shares, representing approximately 0.14% of the company's stock.
• Several institutional investors have increased their stakes in Taysha Gene Therapies, with Bank of America Corp DE raising its position by 1,178.9% in the fourth quarter.
• Taysha Gene Therapies reported a loss of ($0.09) per share for the quarter, which was worse than analysts’ expectations of ($0.07), despite reporting revenue of $1.99 million.

Kovitz Investment Group Partners LLC bought a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 292,778 shares of the company's stock, valued at approximately $407,000. Kovitz Investment Group Partners LLC owned 0.14% of Taysha Gene Therapies at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in TSHA. LPL Financial LLC acquired a new position in shares of Taysha Gene Therapies during the 4th quarter worth approximately $104,000. Geode Capital Management LLC raised its stake in Taysha Gene Therapies by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company's stock valued at $6,182,000 after purchasing an additional 9,591 shares during the last quarter. Wells Fargo & Company MN raised its stake in Taysha Gene Therapies by 43.7% in the 4th quarter. Wells Fargo & Company MN now owns 103,384 shares of the company's stock valued at $179,000 after purchasing an additional 31,457 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Taysha Gene Therapies in the 4th quarter valued at $1,520,000. Finally, Barclays PLC raised its stake in Taysha Gene Therapies by 35.6% in the 4th quarter. Barclays PLC now owns 335,238 shares of the company's stock valued at $587,000 after purchasing an additional 87,958 shares during the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Trading Up 0.3%

Shares of TSHA traded up $0.01 during midday trading on Wednesday, reaching $2.97. The company had a trading volume of 1,269,705 shares, compared to its average volume of 2,918,885. Taysha Gene Therapies, Inc. has a 1-year low of $1.05 and a 1-year high of $3.31. The stock has a market cap of $810.22 million, a PE ratio of -8.74 and a beta of 0.98. The firm has a 50 day simple moving average of $2.65 and a 200-day simple moving average of $2.19. The company has a quick ratio of 12.48, a current ratio of 12.48 and a debt-to-equity ratio of 0.17.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02). The company had revenue of $1.99 million during the quarter, compared to analyst estimates of $1.61 million. Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%. Research analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on TSHA shares. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, July 1st. Chardan Capital increased their price objective on Taysha Gene Therapies from $9.00 to $10.00 and gave the company a "buy" rating in a research note on Tuesday, August 12th. Wells Fargo & Company increased their price objective on Taysha Gene Therapies from $7.50 to $8.00 and gave the company an "overweight" rating in a research note on Wednesday, August 13th. Citigroup reissued an "outperform" rating on shares of Taysha Gene Therapies in a research note on Thursday, May 29th. Finally, JMP Securities increased their price objective on Taysha Gene Therapies from $5.00 to $6.00 and gave the company a "market outperform" rating in a research note on Thursday, May 29th. Eight equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $8.29.

Insider Activity

In other Taysha Gene Therapies news, major shareholder Paul B. Manning acquired 750,000 shares of the business's stock in a transaction that occurred on Friday, May 30th. The stock was purchased at an average cost of $2.75 per share, with a total value of $2,062,500.00. Following the transaction, the insider owned 2,841,704 shares of the company's stock, valued at $7,814,686. This trade represents a 35.86% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 3.78% of the company's stock.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.